Alemtuzumab and Rituximab in Aplastic Anemia

Hospital Universitario Dr. Jose E. Gonzalez

Status: Withdrawn

Conditions: Aplastic Anemia

Treatments: Drug: Alemtuzumab and Rituximab

Study type: Interventional

Funder types: Other

Identifiers

NCT01408342

AA

HE11015

Details and patient eligibility

About

The purpose of the study is to evaluate the efficacy of combination of alemtuzumab and rituximab as first line therapy in aplastic anemia.

Sex: All

Ages: 12+ months old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with aplastic anemia diagnosis

Exclusion criteria

• Patients with prior treatment with monoclonal antibodies and/or antithymocyte globulin.
• Patients with a diagnosis or history of HIV/AIDS, Hepatitis B, Hepatitis C, Cytomegalovirus.
• Patients who do not agree to sign a Letter of Informed Consent.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Rituximab, Alemtuzumab

Other group

Treatment:

Drug: Alemtuzumab and Rituximab